Leading Innovation Target healthcare systems and endoscopy centers focusing on Barrett’s esophagus and esophageal dysplasia surveillance, highlighting CDx’s WATS3D platform as a proven, high-sensitivity adjunct to standard biopsies that increases detection and may improve patient outcomes.

Clinical Validation Leverage recent DDW 2025 data presentations and ongoing trials to position CDx as evidence-backed for provider education and payer conversations, emphasizing added diagnostic yield and AI-assisted 3D cytopathology.

Cost and Reimbursement Emphasize affordability and broad reimbursement of CDx tests to payer stakeholders, presenting the platform as a cost-effective solution that can reduce unnecessary cancer deaths and potentially lower downstream treatment costs.

Strategic Partnerships Explore collaborations with gastroenterology groups, hospital systems, and endoscopy networks to scale WATS3D adoption, leveraging the large tissue sampling advantages and AI-driven analysis to differentiate in competitive markets.

Expansion Opportunities Highlight opportunities to expand beyond Barrett’s esophagus into other precancerous indications (bile duct, stomach, IBD-associated colon) with CDx’s platform, informing multi-site rollouts and integration with existing pathology workflows.